February 12, 2020 / 10:16 PM / in 9 days

BRIEF-Hepion Pharma Says Announced Advancement To Third Dose Level In Its Ongoing Clinical Trial Of Crv431 - SEC Filing

Feb 12 (Reuters) - Hepion Pharmaceuticals Inc:

* HEPION PHARMACEUTICALS INC SAYS ANNOUNCED ADVANCEMENT TO THIRD DOSE LEVEL IN ITS ONGOING CLINICAL TRIAL OF CRV431 - SEC FILING

* HEPION PHARMACEUTICALS - CLINICAL TRIAL MANAGEMENT TEAM HAS REVIEWED 150 MG COHORT DATA AND DETERMINED THIS DOSING LEVEL TO BE SAFE AND WELL TOLERATED Source text: (bit.ly/38iEyya) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below